17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)
Linong Ji(Peking University), WEIPING JIA, Fuyan Shi, Qifu Li(Hainan Medical University), Xin Sheng Li, Kuanzhi Liu, Weihong Song(Wenzhou Medical University), Haoming Tian(Sichuan University), Qing Su(Shanghai Jiao Tong University), Wei Li(Bethune International Peace Hospital), Hongmei Li, Zhiguang Zhou(Central South University), Gangyi Yang(Dalian Medical University), Yanjun Liu(Nankai University), XIANPING LU, Shuying Li(Institute of Food Science and Technology), Xīn Gào(Qingdao University), Tao Yang(Jiangsu Province Hospital), Yangang Wang(Qingdao University), Xuejun Li(Tianjin Medical University), Lian Guo, Jianlin Geng, Hui Fang(Nantong University), Cai H, YAN CHENG XU, Qiu-he Ji, Wenbo Wang, ZHIQIANG NING, Zunhai Zhou
Cited by 5
Related Papers
Prevalence of Diabetes among Men and Women in China
|New England Journal of Medicine|2010|3.1k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease
|Nature Medicine|2002|768
Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease
|The International Journal of Neuropsychopharmacology|2011|430
Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling
|The Journal of Cell Biology|2009|406